SCHEMBL54834

SCHEMBL54834

CC(C)(C)OC(=O)NCc1ccc(N)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
PPIB P23284 1/20 0.52
PPIA P62937 1/20 0.52
PPID Q08752 1/20 0.52
PPIG Q13427 1/20 0.52
GAA P10253 1/20 0.52
NAMPT P43490 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 1/20 0.52
HDAC1 Q13547 2/20 0.51
KDM4A O75164 1/20 0.46
MAPT P10636 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
BRD4 O60885 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7423300 0.98 EPHX2 (0.54) EPHX2L3MBTL1PPIBPPIAPPID
SCHEMBL18664387 0.95 HDAC1 (0.53) EPHX2L3MBTL1PPIBPPIAPPID
SCHEMBL3180689 0.91 L3MBTL1 (0.61) L3MBTL1GAANAMPTCA1CA2
SCHEMBL24414110 0.91 L3MBTL1 (0.48) EPHX2L3MBTL1PPIBPPIAPPID
SCHEMBL26185851 0.89 HDAC1 (0.66) EPHX2L3MBTL1GAANAMPTCA1
SCHEMBL8138303 0.87 L3MBTL1 (0.52) L3MBTL1GAANAMPTCA1CA2
SCHEMBL99337 0.87 TPSAB1 (0.56) L3MBTL1GAANAMPTCA1CA2
SCHEMBL30905374 0.87 L3MBTL1 (0.54) EPHX2L3MBTL1GAANAMPTCA1
SCHEMBL13781495 0.87 L3MBTL1 (0.54) L3MBTL1GAANAMPTCA1CA2
SCHEMBL2213535 0.87 NAMPT (0.65) EPHX2L3MBTL1NAMPTHDAC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118598104-A Lithium iron phosphate composite material, preparation method thereof, positive electrode plate and secondary battery 深圳市德方纳米科技股份有限公司 2024-09-06 CN claimed
EP-4171538-B1 SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS UNIV ILLINOIS (US) 2026-04-29 EP disclosed
EP-4073062-B1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2026-04-29 EP disclosed
US-12570647-B2 Amino benzothiazole compounds for treatment of antibiotic resistant bacteria SAINT LOUIS UNIVERSITY (US) 2026-03-10 US disclosed
EP-3725798-B1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2026-03-04 EP disclosed
EP-4698520-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF Gandeeva Therapeutics, Inc. (US) 2026-02-25 EP disclosed
US-20260015352-A1 METHYLTRANSFERASE INHIBITOR AND USE THEREOF CYTOSINLAB THERAPEUTICS CO LTD (CN) 2026-01-15 US disclosed
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 US disclosed
EP-4667495-A2 BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-12-24 EP disclosed
WO-2025243042-A1 COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D THE UNIVERSITY OF LIVERPOOL (GB) 2025-11-27 WO disclosed
WO-1996002511-A1 NOVEL N1 DIVERSE 6-FLUORINE-8-DIFLUOROMETHOXY SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 1996-02-01 WO disclosed
WO-1996002510-A1 NOVEL 1-[4(AMINO METHYL)PHENYL] SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 1996-02-01 WO disclosed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 EP disclosed
EP-0642508-A1 TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1995-03-15 EP disclosed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO disclosed
EP-0593603-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-04-27 EP disclosed
US-5298409-A Of esters, antigen diastereomers which are stable analogs of the unstable ester transition states THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-03-29 US disclosed
WO-1993008188-A1 TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1993-04-29 WO disclosed
US-5190865-A Antibody-enhanced stereospecific hydrolyses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1993-03-02 US disclosed
WO-1993000095-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570647-B2 Amino benzothiazole compounds for treatment of antibiotic resistant bacteria BCAT1, BCAT2, IL4I1 EPHX2 3521/4885L3MBTL1 59/4885PPIB 2075/4885
US-20260015352-A1 METHYLTRANSFERASE INHIBITOR AND USE THEREOF EZH2, DOT1L, EHMT1 EPHX2 870/4885L3MBTL1 279/4885PPIB 4132/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B EPHX2 316/4885L3MBTL1 1354/4885PPIB 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.